Simcere Pharmaceutical Group.

$SCR - NYSE - Pharmaceuticals and Biotechnology
0 LAST
0 CHANGE $
0 CHANGE %
loader
ON 0
WATCHLISTS

COMMUNIQUÉ DETAILS

Up 0 0 Down
Simcere Pharmaceutical Group Reports Preliminary Unaudited Fourth Quarter And Full Year 2012 Results

NANJING, China, March 7, 2013 /PRNewswire/ -- Simcere Pharmaceutical Group ("Simcere" or the "Company") (NYSE: SCR), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today reported preliminary unaudited financial results for the fourth quarter and full year ended December 31, 2012.

Highlights

  • Total revenue was RMB540.1 million (US$86.7 million) for the fourth quarter of 2012, compared to RMB511.0 million for the same period in 2011, representing an increase of 5.7%. For the full year of 2012, total revenue was RMB2,083.0 million (US$334.3 million), representing an increase of 2.1% from RMB2,040.5 million  in 2011.
  • Gross margin for the fourth quarter of 2012 was 81.1%, compared to 82.3% for the same period in 2011. For the full year of 2012, gross margin was 82.7%, compared to 83.9% in 2011.

  • Loss from operations for the fourth quarter of 2012 was RMB78.2 million (US$12.5 million), primarily due to a non-cash impairment charge of RMB97.2 million(US$15.6 million), as the result of a write-down of intangible assets, goodwill, and assets held for sale associated with the acquisition of Jiangsu Quanyi Biological Technology Stock Co., Ltd. ("Jiangsu Quanyi") in 2009. For the full year of 2012, income from operations was RMB39.6 million (US$6.4 million), which represented a decrease of 72.4% from RMB143.5 million in 2011.

  • Net loss attributable to Simcere for the fourth quarter of 2012 was RMB20.8 million (US$3.3 million), compared to net income attributable to Simcere of RMB42.8 million for the same period in 2011. For the full year of 2012, net income attributable to Simcere was RMB57.0 million (US$9.1 million), which represented a decrease of 68.1% from RMB178.4 million in 2011.

Mr. Hongquan Liu, Executive Director and Chief Executive Officer of Simcere Pharmaceutical Group, commented, "With the ongoing implementation of a series of healthcare reform policies, drug prices continued to trend down in 2012. Despite the challenging environment and intense competition, our sales in the fourth quarter grew moderately. While we believe market conditions will remain challenging in 2013, our priorities will continue to be strengthening promotion of our key products, accelerating market access and hospital listings, and reducing costs."

The Company also announced that Mr. Alan Au joined the Company as an independent director and chairman of the audit committee in March 2013. Mr. Au has over 15 years of experience in the financial service and investment sectors relating to healthcare in Asia. He is a Certified Public Accountant in the U.S. and holds the Chartered Financial Analyst designation. Mr. Au received his Bachelor's degree in Psychology from the Chinese University of Hong Kong in 1995, and a Master's degree in Management from Columbia University in 2007.

2012 Fourth Quarter and Full Year Financial Results

Total revenue for the fourth quarter of 2012 was RMB540.1 million (US$86.7 million), compared to RMB511.0 million for the same period in 2011, representing an increase of 5.7%. For the full year of 2012, total revenue was RMB2,083.0 million (US$334.3 million), representing an increase of 2.1% from RMB2,040.5 million  in 2011.

The tables below set forth the Company's top 10 products by revenue for the three months ended December 31, 2012 and the year ended December 31, 2012:

In Thousands




Three months ended December 31, 2012


Three months ended December 31, 2011




RMB


USD


% of total


RMB


% of total

Change

Products

Therapeutic Area






revenue




revenue


Edaravone

Neuroscience


184,601


29,631


34.2%


172,303


33.7%

7.1%

Endu

Oncology


77,567


12,450


14.4%


65,397


12.8%

18.6%

Zailin

Infectious Disease


53,642


8,610


9.9%


56,790


11.1%

(5.5%)

Yintaiqing

Inflammation


48,686


7,814


9.0%


56,443


11.0%

(13.7%)

Sinofuan

Oncology


38,244


6,139


7.1%


42,789


8.4%

(10.6%)

Biqi

Gastroenterology


19,622


3,149


3.6%


11,786


2.3%

66.5%

Jiebaishu

Oncology


15,772


2,532


2.9%


18,696


3.7%

(15.6%)

Kechuanning

Respiratory


13,132


2,108


2.4%


13,351


2.6%

(1.6%)

Anqi

Infectious Disease


11,073


1,777


2.1%


12,957


2.5%

(14.5%)

Anxin

Infectious Disease


10,722


1,721


2.0%


10,877


2.1%

(1.4%)

Others



67,079


10,767


12.4%


49,631


9.8%

35.2%

Total



540,140


86,698


100.0%


511,020


100.0%

5.7%




Year ended December 31, 2012


Year ended December 31, 2011




RMB


USD


% of total


RMB


% of total  

  Change

Products

Therapeutic Area






revenue




revenue


Edaravone

Neuroscience


702,698


112,791


33.7%


770,967


37.8%

(8.9%)

Endu

Oncology


271,214


43,533


13.0%


263,046


12.9%

3.1%

Zailin

Infectious Disease


229,303


36,806


11.0%


191,006


9.4%

20.1%

Yintaiqing

Inflammation


177,884


28,552


8.5%


185,441


9.1%

(4.1%)

Sinofuan

Oncology


159,884


25,663


7.7%


178,146


8.7%

(10.3%)

Biqi

Gastroenterology


86,242


13,843


4.1%


82,034


4.0%

5.1%

Jiebaishu

Oncology


69,553


11,164


3.4%


68,344


3.3%

1.8%

Anxin

Infectious Disease


56,396


9,052


2.7%


45,919


2.3%

22.8%

Anqi

Infectious Disease


51,495


8,265


2.5%


58,592


2.9%

(12.1%)

Kechuanning

Respiratory


46,357


7,441


2.2%


42,268


2.0%

9.7%

Others



231,940


37,229


11.2%


154,784


7.6%

49.8%

Total



2,082,966


334,339


100.0%


2,040,547


100.0%

2.1%

 

For more information about the above products, please visit the Company's corporate website:

www.simcere.com.

Gross margin for the fourth quarter of 2012 was 81.1%, compared to 82.3% for the same period in 2011. For the full year of 2012, gross margin was 82.7%, compared to 83.9% in 2011.

Research and development expenses for the fourth quarter of 2012 totaled RMB60.2 million (US$9.7 million) which represented a decrease of 14.7% from RMB70.6 million for the same period in 2011. This was due primarily to an addition of RMB7.9 million (US$1.3 million) in government research and development grants recognized compared to the same period in 2011. As a percentage of total revenue, research and development expenses decreased to 11.1% for the fourth quarter of 2012 from 13.8% for the same period in 2011. For the full year of 2012, research and development expenses totaled RMB228.7 million (US$36.7 million), compared to RMB198.7 million in 2011.

Sales, marketing and distribution expenses for the fourth quarter of 2012 were RMB284.5 million (US$45.7 million), which represented a decrease of 1.0% from RMB287.4 million for the same period in 2011. As a percentage of total revenue, sales, marketing and distribution expenses decreased to 52.7% for the fourth quarter of 2012 from 56.2% for the same period in 2011. For the full year of 2012, sales, marketing and distribution expenses were RMB1,140.8 million (US$183.1 million), which represented an increase of 0.8% from RMB1,132.0 million in 2011.

General and administrative expenses were RMB74.4 million (US$11.9 million) for the fourth quarter of 2012, which represented a decrease of 1.8% from RMB75.8 million for the same period in 2011. As a percentage of total revenue, general and administrative expenses decreased to 13.8% for the fourth quarter of 2012 from 14.8% for the same period in 2011. For the full year of 2012, general and administrative expenses were RMB256.0 million (US$41.1 million), which represented a decrease of 11.2% from RMB288.1 million in 2011.

Share-based compensation expenses, which were allocated to research and development expenses, sales, marketing and distribution expenses, and general and administrative expenses, based on the nature of the work that the relevant employee was assigned to perform, totaled RMB10.0 million (US$1.6 million) for the fourth quarter of 2012, compared to RMB6.3 million for the same period in 2011, which was primarily due to new issuance of restricted shares. For the full year of 2012, share-based compensation expenses totaled RMB20.4 million (US$3.3 million), a decrease of 30.4% from RMB29.3 million in 2011, which was primarily due to the completion of the vesting period of the first and second batches of restricted shares in November 2011 and March 2012, respectively.

Loss from operations for the fourth quarter of 2012 was RMB78.2 million (US$12.5 million), compared to income from operations of RMB1.6 million for the same period in 2011. Loss from operations was primarily attributable to a non-cash impairment charge of RMB97.2 million (US$15.6 million) as the result of a write-down of intangible assets, goodwill, and assets held for sale associated with the acquisition of Jiangsu Quanyi in 2009. Simcere has determined a write-down of assets and goodwill of Jiangsu Quanyi is required due to lowered expectation for future sales and profitability of its vaccine products currently under development. For the full year of 2012, income from operations was RMB39.6 million (US$6.4 million), which represented a decrease of 72.4% from RMB143.5 million in 2011.

Income tax benefit for the fourth quarter of 2012 was RMB11.9 million (US$1.9 million), compared to income tax benefit of RMB41.9 million for the same period in 2011. The significant income tax benefit in the fourth quarter of 2011 was primarily due to the improved financial results at one of the Company's subsidiaries during 2011, resulting in the reversal of the valuation allowance previously made against the deferred tax assets of this subsidiary amounting to RMB32.3 million in the fourth quarter of 2011. For the full year of 2012, income tax benefit was RMB5.6 million (US$0.9 million), compared to income tax benefit of RMB35.4 million in 2011.

Net loss attributable to Simcere for the fourth quarter of 2012 was RMB20.8 million (US$3.3 million), compared to net income attributable to Simcere of RMB42.8 million for the same period in 2011. The net loss, as mentioned previously, was primarily attributable to the non-cash impairment charge of RMB97.2 million (US$15.6 million) as the result of a write-down of intangible assets, goodwill and assets held for sale associated with the acquisition of Jiangsu Quanyi in 2009. For the full year of 2012, net income attributable to Simcere was RMB57.0 million (US$9.1 million), which represented a decrease of 68.1% from RMB178.4 million in 2011. Net margin, representing net income attributable to Simcere divided by total revenue, for the full year of 2012 was 2.7%, compared to 8.7% in 2011.

Basic and diluted net loss per American Depository Share ("ADS") for the fourth quarter of 2012 were RMB 0.40 (US$0.06) and RMB 0.39 (US$0.06), respectively. Basic and diluted earnings per ADS for the full year of 2012 were RMB1.06 (US$0.17) and RMB1.06 (US$0.17), respectively. One ADS represents two ordinary shares of the Company.

As of December 31, 2012, the Company had cash, cash equivalents and restricted cash of RMB201.6 million (US$32.4 million), compared to RMB262.6 million as of December 31, 2011.

Financial Information

The preliminary unaudited condensed consolidated statements of income and balance sheets accompanying this press release have been prepared by management using U.S. GAAP. This preliminary financial information is not intended to fully comply with U.S. GAAP because it does not present all of the financial information and disclosures required by U.S. GAAP.

Safe Harbor Statement

This press release contains forward-looking statements. These statements constitute "forward-looking" statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "anticipate," "believe," "estimate," "expect," "forecast," "intend," "may," "plan," "project," "predict," "should" and "will" and similar expressions. In particular, the quotations from management in this press release contain forward-looking statements. These forward looking statements are based upon management's current views and expectations with respect to future events and are not a guarantee of future performance. Furthermore, these statements are, by their nature, subject to a number of risks and uncertainties that could cause actual performance and results to differ materially from those discussed in the forward-looking statements as a result of a number of factors. Further information regarding these and other risks is included in Simcere's filings with the U.S. Securities and Exchange Commission at www.sec.gov. Simcere does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

Conference Call

Simcere Pharmaceutical Group will host a conference call to discuss the Company's results for the fourth quarter and full year of 2012 on Thursday, March 7, 2013 at 8:00 a.m. Eastern Time (Thursday, March 7 at 9:00 p.m. Beijing/Hong Kong time). The management team will be on the call to discuss the results for the fourth quarter and full year of 2012 and to answer questions.

To access the conference call, please dial:

International toll:                                

+65.6723.9381

United States toll-free:                        

+1.866.519.4004

United States toll:                              

+1.718.354.1231

China Domestic toll-free:                     

800.819.0121

China Domestic mobile toll-free:       

400.620.8038

Hong Kong toll:                                 

+852.2475.0994

Please ask to be connected to Q4 2012 Simcere Pharmaceutical Group Earnings Conference Call and provide the following passcode: 12783585.

Simcere will also broadcast a live audio webcast of the conference call. The broadcast will be available by visiting the "Investor Relations" section of the company's web site at www.simcere.com.

Following the earnings conference call, an archive of the call will be available by dialing:

United States toll-free:                        

+1.855.452.5696

United States toll:                       

+1.646.254.3697

The passcode for replay participants is 12783585. The telephone replay also will be archived on the "Investor Relations" section of the company's website for seven days following the earnings announcement.

About Simcere Pharmaceutical Group

Simcere Pharmaceutical Group (NYSE: SCR, Simcere) is a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, cardiovascular disease, infectious diseases and pain. For more information about Simcere Pharmaceutical Group, please visit www.simcere.com.

Investor and Media Contacts:
Email: ir@simcere.com

In Nanjing:   

In the United States:

Jie Liu D'Elia   

Cindy Zheng

Vice President

Brunswick Group

Simcere Pharmaceutical Group  

Tel: 1-212-333-3810

Tel: 86-25-8556-6666*8857






In Beijing: 


Yue Yu


Brunswick Group


Tel: 86-10-5960-8600


 

 

Simcere Pharmaceutical Group

PRELIMINARY UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(Amounts expressed IN THOUSANDS, EXCEPT SHARE AND ADS DATA)  


Three months ended December 31,


Year ended December 31,


2011

2012

2012


2011

2012

2012


RMB

RMB

USD


RMB

RMB

USD

Product revenue

511,020

540,140

86,698


2,040,547

2,082,966

334,339

Total revenue

511,020

540,140

86,698


2,040,547

2,082,966

334,339

Cost of materials and production

(90,614)

(101,935)

(16,361)


(328,159)

(361,071)

(57,956)

Gross profit

420,406

438,205

70,337


1,712,388

1,721,895

276,383









Operating expenses and other operating income:








Research and development

(70,583)

(60,216)

(9,666)


(198,722)

(228,717)

(36,711)

Sales, marketing and distribution

(287,428)

(284,518)

(45,668)


(1,131,974)

(1,140,810)

(183,113)

General and administrative

(75,784)

(74,384)

(11,940)


(288,144)

(255,999)

(41,091)

Impairment on goodwill, intangible assets

and assets held for sale

-

(97,247)

(15,609)


-

(97,247)

(15,609)

Other operating income

15,000

-

-


50,000

40,439

6,491

Income/(loss)  from operations

1,611

(78,160)

(12,546)


143,548

39,561

6,350









Interest income

1,036

1,256

202


4,676

4,066

653

Interest expense

(11,034)

(13,897)

(2,231)


(42,342)

(69,258)

(11,117)

Foreign currency exchange gains/(losses)

1,108

(81)

(13)


7,732

(923)

(148)

Other  income

846

3,244

521


15,036

11,429

1,834

Equity in (losses)/incomes of equity method
affiliated
company

(1,974)

6,062

973


(12,192)

(4,859)

(780)

Income/(loss)  before income taxes

 

(8,407)

(81,576)

(13,094)


116,458

(19,984)

(3,208)









Income tax benefit

41,866

11,919

1,913


35,371

5,581

896

Net Income/(loss)         

33,459

(69,657)

(11,181)


151,829

(14,403)

(2,312)









Less: Net loss attributable to the      
          noncontrolling interest

9,338

48,857

7,842


26,560

71,360

11,454

Net income/(loss) attributable to Simcere

42,797

(20,800)

(3,339)


178,389

56,957

9,142









Income/(loss)  per share attributable to Simcere:








Basic

0.39

(0.20)

(0.03)


1.63

0.53

0.09

Diluted

0.39

(0.20)

(0.03)


1.61

0.53

0.09









Income/(loss)  per ADS attributable to Simcere:








Basic

0.78

(0.40)

(0.06)


3.25

1.06

0.17

Diluted

0.77

(0.39)

(0.06)


3.23

1.06

0.17









Weighted average number of common shares: Basic

109,941,646

105,220,991

105,220,991


109,738,705

106,996,531

106,996,531

Diluted

110,477,166

105,764,663

105,764,663


110,525,257

107,370,830

107,370,830

 

 

SIMCERE PHARMACEUTICAL GROUP

PRELIMINARY UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

(AMOUNTS EXPRESSED IN THOUSANDS)

 


   December 31,

   December 31,

   December 31,


2011

RMB

2012

RMB

2012

USD





Assets




Current assets




Cash, cash equivalents and restricted cash

262,557

201,556

32,352

Assets held for sale

-

90,550

14,534

Bills receivable

814,822

679,630

109,088

Accounts receivable, net

462,050

413,481

66,368

Inventories

126,708

120,932

19,411

Other current assets

181,196

237,248

38,081

Total current assets

1,847,333

1,743,397

279,834

Property, plant and equipment, net

925,815

853,546

137,004

Land use rights

139,707

128,220

20,581

Goodwill and intangible assets, net

648,408

519,334

83,359

Investments in and advance to an affiliated company

91,355

56,785

9,115

Other non-current assets

81,499

71,381

11,457

Total assets

3,734,117

3,372,663

541,350

Liabilities




Current liabilities




Short-term borrowings and current portion of long-term  
   borrowings

816,150

675,779

108,470

Accounts payable

52,191

47,136

7,566

Bills payable

28,379

15,000

2,408

Other payables and accrued liabilities

565,827

471,603

75,697

Total current liabilities

1,462,547

1,209,518

194,141

Long-term borrowings, excluding current portion

-

2,000

321

Deferred tax liabilities

46,248

56,120

9,008

Other liabilities

31,625

32,657

5,242

Total liabilities

1,540,420

1,300,295

208,712

Shareholders' equity




Simcere shareholders' equity




Ordinary shares at par

8,532

8,258

1,326

Additional paid-in capital

954,750

853,551

137,004

Accumulated other comprehensive loss

(104,608)

(104,147)

(16,717)

Retained earnings

1,197,507

1,254,464

201,355

Total equity attributable to Simcere

2,056,181

2,012,126

322,968

Noncontrolling interest

137,516

60,242

9,670

Total shareholders' equity

2,193,697

2,072,368

332,638

Commitments and contingencies




Total liabilities and shareholders' equity

3,734,117

3,372,663

541,350

Note: The conversions of Renminbi (RMB) into United States dollars (USD) as at the reporting dates are based on the noon buying rate of USD1.00 = RMB6.2301 on December 31, 2012 as set forth in the H. 10 statistical release of the Federal Reserve Board. No representation is intended to imply that the RMB amounts could have been, or could be, converted, realized or settled into U.S. dollars at that rate on the reporting dates.

SOURCE Simcere Pharmaceutical Group

SHARE THIS: Twitter StockTwits LinkedIn Google Plus SHORT URL: http://bdvt.co/biPD

SIGN IN TO BOARDVOTE

FORGOT PASSWORD?